Spain-based Gyala Therapeutics Raises €3M Funding

The company has raised €3 million in funding to advance its innovative therapies, aiming to improve treatment outcomes for patients with blood cancers and strengthen its research and development capabilities.

Founded in 2020, Gyala Therapeutics is a spin-off from Hospital Clínic IDIBAPS in Barcelona, developing new CAR-T therapies for blood cancers. The company has raised around €8 million through investors like Invivo Partners, Nara Capital and CDTI Innvierte, along with support from national innovation programs such as NEOTEC.

Read Also - Byome Labs Raises €3.6M To Expand Skin Microbiome Technology For Personalized Skincare

"The preclinical evidence confirms that GYA01 is a highly promising CAR-T therapy, supports CD84 as a pan-hematological target, and establishes a strong foundation for advancing to clinical trials," said Dr. Nela Klein-Gonzalez, Chief Medical Officer of Gyala Therapeutics and lead author of the publication.

The funding round was supported by Invivo Partners, Nara Capital, and CDTI Innvierte. Gyala Therapeutics plans to use the investment to expand its operations and R&D activities.

Gyala Therapeutics, led by CEO Claudio Santos, is a biotechnology company developing immunotherapies for hematological cancers with unmet medical needs.

Claudio Santos, PhD, CEO of Gyala Therapeutics, added: "Our next goal is to launch a clinical trial of GYA01 in AML patients at Hospital Clinic Barcelona and Hospital La Fe in Valencia, bringing this therapy to patients with aggressive leukemias who lack alternatives."

Its lead program, GYA01, is a CAR T-cell therapy targeting the CD84 protein, a promising target in acute myeloid leukemia, T-cell acute lymphoblastic leukemia, and other blood cancers due to its high expression in malignant cells and low expression in healthy stem cells.

About Gyala Therapeutics

Gyala Therapeutics is a biotechnology company focused on developing innovative cell therapies for blood cancers. By leveraging advanced CAR-T technology the company aims to target malignant cells precisely, offering new treatment options for hematological malignancies and addressing unmet medical needs while advancing research and improving patient outcomes.